Literature DB >> 2524602

Complications of whole bladder dihematoporphyrin ether photodynamic therapy.

J I Harty1, M Amin, T J Wieman, M T Tseng, D Ackerman, W Broghamer.   

Abstract

Photodynamic therapy with dihematoporphyrin ether was used to treat superficial bladder tumors in 7 patients with a followup of at least 1 year. Each patient received treatment to the whole bladder and those with papillary lesions received additional focal treatment. At 3 months 4 of the 5 patients with papillary tumors (stages Ta and T1) and 1 of the 2 with diffuse carcinoma in situ (Tis) were free of disease. However, at 1 year only 3 patients remained free of disease. Of 5 patients with an increase in irritative bladder symptoms 4 had a contracted bladder, hydroureteronephrosis and vesicoureteral reflux. Deep bladder biopsies showed replacement of smooth muscle by fibrous tissue. Six patients had mild to moderate skin phototoxicity. We conclude that although photodynamic therapy is an attractive and exciting method to treat cancer, its use with dihematoporphyrin ether in cases of bladder carcinoma can be associated with significant complications. The correct treatment parameters for safe, effective therapy are not known to date.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524602     DOI: 10.1016/s0022-5347(17)41302-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Authors:  Peter H Ahn; Harry Quon; Bert W O'Malley; Gregory Weinstein; Ara Chalian; Kelly Malloy; Joshua H Atkins; Thomas Sollecito; Martin Greenberg; Sally McNulty; Alexander Lin; Timothy C Zhu; Jarod C Finlay; Keith Cengel; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Theresa M Busch
Journal:  Oral Oncol       Date:  2016-02-08       Impact factor: 5.337

2.  The photodynamic effect of a pulsed dye laser on human bladder carcinoma cells in vitro.

Authors:  A J Pope; J R Masters; A J MacRobert
Journal:  Urol Res       Date:  1990

3.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

4.  Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer.

Authors:  R Bachor; R Hautmann; T Hasan
Journal:  Urol Res       Date:  1994

5.  Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.

Authors:  S N Datta; R Allman; C Loh; M Mason; P N Matthews
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy.

Authors:  A J Pope; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

Review 7.  New Designs for Phototherapeutic Transition Metal Complexes.

Authors:  Cinzia Imberti; Pingyu Zhang; Huaiyi Huang; Peter J Sadler
Journal:  Angew Chem Int Ed Engl       Date:  2019-09-24       Impact factor: 16.823

8.  Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitiser dose and time of administration.

Authors:  F A Stewart; Y Oussoren
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

9.  Functional and histological damage in the mouse bladder after photodynamic therapy.

Authors:  F A Stewart; Y Oussoren; J A te Poele; S Horenblas; W J Mooi
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  The effect of aminolaevulinic acid-induced, protoporphyrin IX-mediated photodynamic therapy on the cremaster muscle microcirculation in vivo.

Authors:  J Leveckis; N J Brown; M W Reed
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.